COMPANY

Allogene Therapeutics

HQ: South San Francisco, CA source · allogene.com ↗

Keywords: oncology renal metastatic clear cell renal cell carcinoma immunology cancer autoimmune disease Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Large B Cell Lymphoma Large B-cell Lymphoma Systemic Lupus Erythematosus (With and Without Nephritis) Idiopathic Inflammatory Myopathy Systemic Sclerosis Advanced/Metastatic Clear Cell Renal Cell Carcinoma Relapsed/Refractory Follicular Lymphoma Hematologic Malignancies ALLO-647 ALLO-501A ALLO-329 ALLO-316 ALLO-715 ALLO-501 ALLO-605

Location: South San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$200.4MRaised (2 yrs)9Trials (company is sponsor)

Timeline

Apr 16, 2026 Raise Follow-on offering: $200.4M (total, as published), announced Apr 16, 2026. Source: company release on GlobeNewswire. source ↗
Nov 13, 2025 Trial start Phase 1: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease source ↗
Jan 31, 2025 Trial start —: Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product source ↗
Jun 18, 2024 Trial start Phase 2: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL source ↗
Nov 1, 2023 Trial start Phase 2: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy source ↗
Jun 6, 2021 Trial start Phase 1/Phase 2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma source ↗
Feb 24, 2021 Trial start Phase 1: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma source ↗
May 21, 2020 Trial start Phase 1/Phase 2: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma source ↗
Sep 23, 2019 Trial start Phase 1: Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) source ↗
May 1, 2019 Trial start Phase 1: Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Phase 2 · Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL · NCT06500273
2028-02 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease · NCT07085104
2029-02 (ESTIMATED) · Phase 1/Phase 2 · Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) · NCT04416984
2030-01 (ESTIMATED) · Phase 1 · Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma · NCT04696731
2039-01 (ESTIMATED) · · Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product · NCT06925685

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $200.4M. Last 2 years.

Apr 16, 2026 Follow-on offering: $200.4M (total, as published), announced Apr 16, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT06500273	Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL	Phase 2	Recruiting	Jun 18, 2024	2027-12 (estimated)
NCT07085104	A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease	Phase 1	Recruiting	Nov 13, 2025	2028-02 (estimated)
NCT04696731	Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma	Phase 1	Active, not recruiting	Feb 24, 2021	2030-01 (estimated)
NCT04093596	Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)	Phase 1	Completed	Sep 23, 2019	Jan 27, 2025 (actual)
NCT04416984	Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)	Phase 1/Phase 2	Active, not recruiting	May 21, 2020	2029-02 (estimated)
NCT05714345	Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy	Phase 2	Terminated	Nov 1, 2023	Feb 20, 2024 (actual)
NCT03939026	Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma	Phase 1	Completed	May 1, 2019	Oct 23, 2021 (actual)
NCT06925685	Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product	Not listed	Enrolling by invitation	Jan 31, 2025	2039-01 (estimated)
NCT05000450	Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma	Phase 1/Phase 2	Terminated	Jun 6, 2021	Oct 11, 2023 (actual)